Literature DB >> 28242658

GMP and IMP Are Competitive Inhibitors of CMY-10, an Extended-Spectrum Class C β-Lactamase.

Jung-Hyun Na1, Young Jun An2, Sun-Shin Cha3.   

Abstract

Nucleotides were effective in inhibiting the class C β-lactamase CMY-10. IMP was the most potent competitive inhibitor, with a Ki value of 16.2 μM. The crystal structure of CMY-10 complexed with GMP or IMP revealed that nucleotides fit into the R2 subsite of the active site with a unique vertical binding mode where the phosphate group at one terminus is deeply bound in the subsite and the base at the other terminus faces the solvent.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  GMP; IMP; competitive inhibitor; β-lactamases

Mesh：

Substances：

Year:  2017        PMID： 28242658      PMCID： PMC5404520          DOI： 10.1128/AAC.00098-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase.

Authors:  Jae Young Kim; Ha Il Jung; Young Jun An; Jung Hun Lee; So Jung Kim; Seok Hoon Jeong; Kye Joon Lee; Pann-Ghill Suh; Heung-Soo Lee; Sang Hee Lee; Sun-Shin Cha
Journal:  Mol Microbiol       Date:  2006-05       Impact factor: 3.501

Review 2.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

3.  Structural basis for the extended substrate spectrum of AmpC BER and structure-guided discovery of the inhibition activity of citrate against the class C β-lactamases AmpC BER and CMY-10.

Authors:  Jung Hyun Na; Sun Shin Cha
Journal:  Acta Crystallogr D Struct Biol       Date:  2016-07-28       Impact factor: 7.652

Review 4.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products.

Authors:  M Galleni; F Lindberg; S Normark; S Cole; N Honore; B Joris; J M Frere
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

Review 6.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Structural and mechanistic insights into the inhibition of class C β-lactamases through the adenylylation of the nucleophilic serine.

Authors:  Min-Kyu Kim; Young Jun An; Jung-Hyun Na; Jae-Hee Seol; Ju Yeon Ryu; Jin-Won Lee; Lin-Woo Kang; Kyung Min Chung; Jung-Hyun Lee; Jeong Hee Moon; Jong Seok Lee; Sun-Shin Cha
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

Review 9.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Analysis of the Structure and Function of FOX-4 Cephamycinase.

Authors:  S T Lefurgy; V N Malashkevich; J T Aguilan; E Nieves; E C Mundorff; B Biju; M A Noel; R Toro; D Baiwir; K M Papp-Wallace; S C Almo; J-M Frere; G Bou; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191
View more
  6 in total

Review 1.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

2.  In vitro and in vivo Inhibitory Activity of NADPH Against the AmpC BER Class C β-Lactamase.

Authors:  Jung-Hyun Na; Tae Hee Lee; Soo-Bong Park; Min-Kyu Kim; Bo-Gyeong Jeong; Kyung Min Chung; Sun-Shin Cha
Journal:  Front Cell Infect Microbiol       Date:  2018-12-21       Impact factor: 5.293

3.  Editorial: Beyond Antimicrobials: Non-traditional Approaches to Combating Multidrug-Resistant Bacteria.

Authors:  Natalia V Kirienko; Laurence Rahme; You-Hee Cho
Journal:  Front Cell Infect Microbiol       Date:  2019-10-11       Impact factor: 5.293

4.  Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae.

Authors:  Nousheen Parvaiz; Faisal Ahmad; Wenbo Yu; Alexander D MacKerell; Syed Sikander Azam
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

Review 5.  Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.

Authors:  Rémy A Bonnin; Agnès B Jousset; Cécile Emeraud; Saoussen Oueslati; Laurent Dortet; Thierry Naas
Journal:  Front Med (Lausanne)       Date:  2021-01-20

6.  Identification of Potential Drug Targets in Helicobacter pylori Using In Silico Subtractive Proteomics Approaches and Their Possible Inhibition through Drug Repurposing.

Authors:  Kareem A Ibrahim; Omneya M Helmy; Mona T Kashef; Tharwat R Elkhamissy; Mohammed A Ramadan
Journal:  Pathogens       Date:  2020-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.